While Edwards Lifesciences raised its outlook based on the latest procedure results, growth in heart valve treatment centered on TAVR has become a focus of shareholder attention.
Edwards Lifesciences raised its 2026 revenue and product-group forecasts. Its procedure-driven growth story has once again attracted market attention, with indications that the earnings base in heart valve treatment, centered on TAVR, will be strengthened.
In the PROGRESS trial, TAVR was superior to clinical surveillance on the composite endpoint of death and heart-failure events in patients with moderate aortic stenosis, and significantly improved quality of life (QOL) 30 days after the procedure. This strengthened the basis for the treatment's use in clinical practice and for expanding demand.
Against a backdrop of expanded Medicare coverage and an upward revision in the growth outlook for TAVR from 9% to 9.5%, changes in procedure volumes were reaffirmed as a major business driver. At the same time, risk factors including tariff risks, costs associated with blocking mergers and acquisitions, and pressure on existing profitability were also identified.
Analysts expect revenue to reach approximately $8.7 billion and net income to approximately $2.3 billion by 2029, based on annual revenue growth of 9.2%. Multiple views have been presented on the relationship between the current share-price valuation and fair value.